Understanding how specific T cells protect against tuberculosis
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
This study is looking at how certain immune cells help protect against tuberculosis, aiming to find better vaccine options for adults at risk of this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10843905 on NIH RePORTER |
What this research studies
This research investigates the role of lipid-specific T cells in providing immunity against Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. The study aims to identify which antigens these T cells target, which is crucial for developing more effective vaccines than the currently used BCG vaccine. By examining how T cells interact with mycobacterial lipids and the CD1 system, the research seeks to uncover new strategies for enhancing immune responses in adults, who are at higher risk for pulmonary tuberculosis. The findings could lead to innovative vaccine designs that better protect against this serious infectious disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who are at risk of developing pulmonary tuberculosis or those who have had previous exposure to tuberculosis.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been effectively vaccinated with BCG may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective vaccine against tuberculosis, significantly reducing infection rates and mortality.
How similar studies have performed: Previous research has shown promise in understanding T cell responses in other infectious diseases, suggesting that this approach could yield valuable insights for tuberculosis as well.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Seshadri, Chetan — University of Washington
- Study coordinator: Seshadri, Chetan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.